• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Kodiak Sciences Inc

    6/3/25 4:29:59 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    8-K
    false 0001468748 0001468748 2025-06-02 2025-06-02
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 2, 2025

     

     

    Kodiak Sciences Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38682   27-0476525

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1250 Page Mill Road

    Palo Alto, CA

      94304
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (650) 281-0850

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.0001   KOD   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On June 2, 2025, Kodiak Sciences Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, proxies representing 43,370,916 shares of the Company’s common stock, or 82.20% of the total shares entitled to vote, were present and voted on the following proposals, which are described in more detail in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 22, 2025:

    Proposal One - Election of Class I Directors.

    The following nominees were each elected as a Class I director to serve until the 2028 annual meeting of stockholders or until his successor is duly elected and qualified.

     

    Nominee    For      Withheld      Broker Non-Votes  

    Richard S. Levy, M.D.

         29,171,558        8,444,575        5,754,783  

    Robert A. Profusek, J.D.

         24,691,172        12,924,961        5,754,783  

    Proposal Two – Advisory Approval of the Compensation of Named Executive Officers.

    The compensation of the Company’s named executive officers was approved, on an advisory basis, by the stockholders.

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    35,200,864   2,365,796   49,473   5,754,783

    Proposal Three – Ratification of the Appointment of Independent Registered Public Accounting Firm.

    The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2025 was ratified.

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    43,031,110   36,185   303,621   —


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          KODIAK SCIENCES INC.
    Date: June 3, 2025     By:  

    /s/ Victor Perlroth

          Victor Perlroth, M.D.
          Chief Executive Officer
    Get the next $KOD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    10/24/2025$24.00Neutral → Overweight
    Analyst
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    9/22/2025$15.00Buy
    Jefferies
    8/14/2025$15.00Underweight → Neutral
    Analyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    More analyst ratings

    $KOD
    SEC Filings

    View All

    SEC Form 10-Q filed by Kodiak Sciences Inc

    10-Q - Kodiak Sciences Inc. (0001468748) (Filer)

    11/13/25 4:12:38 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kodiak Sciences Inc. (0001468748) (Filer)

    11/13/25 4:05:29 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Kodiak Sciences Inc

    SCHEDULE 13G - Kodiak Sciences Inc. (0001468748) (Subject)

    8/19/25 5:26:43 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

    PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution and growing external enthusiasm...across all three of our late-stage programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "Looking ahead, we expect this momentum to continue building as we enter an action-packed 2026 with all three of our Phase 3 assets on track for Phase 3 topline data readouts as well as our first planned BLA filing. On top of

    11/13/25 4:05:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences to Present at Upcoming Investor Conferences

    PALO ALTO, Calif., Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the following upcoming investor conferences: Jefferies Global Healthcare Conference in London, UK Date: Monday, November 17, 2025Time: 4:30pm GMT (8:30am PST)Format: Presentation8th Annual Evercore Healthcare Conference in Coral Gables, FloridaDate: Wednesday, December 3, 2025Time: 3:00pm EST (12pm PST)Format: Fireside chatA live webcast of both presentations will be available on the "Eve

    11/12/25 5:48:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

    Meaningful vision gains are rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with more than half of patients achieving improvement of 3-lines or more on the eye chart (≥15 letter gain).≥90% of patients in the top two dose levels achieved and sustained real dryness of the retina, as demonstrated by absence of intraretinal fluid (IRF) as well as subretinal fluid (SRF), key markers of disease activity.The Phase 3 PEAK and PINNACLE studies of KSI-101 are enrolling at a faster-than-expected pace, evaluating the top two dose levels (5 mg and 10 mg) in patients with MESI.PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Kodia

    11/5/25 7:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kodiak Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $24.00

    11/11/25 8:00:12 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Analyst with a new price target

    Analyst upgraded Kodiak Sciences from Neutral to Overweight and set a new price target of $24.00

    10/24/25 8:56:02 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Barclays with a new price target

    Barclays upgraded Kodiak Sciences from Underweight to Equal Weight and set a new price target of $17.00

    9/25/25 8:23:23 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/24 4:23:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    1/26/24 11:49:38 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/23 4:19:55 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Borgeson John A.

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:33:23 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chairman and CEO Perlroth Victor

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:30:46 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/2/25 5:08:03 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Leadership Updates

    Live Leadership Updates

    View All

    Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

    PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

    9/17/24 4:05:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

    SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

    12/3/20 11:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Financials

    Live finance-specific insights

    View All

    Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

    PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

    3/26/24 6:15:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

    PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

    2/23/22 6:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care